Nigeria Launches New HIV Prevention Injection, Aims for 2030 Eradication Goal
Abuja, Nigeria – Nigeria has begun rolling out Lenacapavir, a new long-acting injectable medication for HIV prevention, marking a significant step in the country’s fight against the virus. The rollout, commencing in eight states – Anambra, Ebonyi, Gombe, Kwara, Akwa Ibom, Cross River, Benue, and the Federal Capital Territory – aims to expand access to innovative prevention options, officials announced Monday.
The six-monthly injection offers a new alternative to daily oral PrEP (pre-exposure prophylaxis), particularly for individuals who find it difficult to adhere to a daily pill regimen. Developed by Gilead Sciences, Lenacapavir is administered as an antiretroviral, preventing HIV infection in those at risk.
However, the Nigerian government has restricted its use for pregnant women due to insufficient safety data. Temitope Ilori, Director-General of the National Agency for the Control of AIDS (NACA), emphasized that while global trials suggest the drug is largely safe, more evidence is needed before it can be recommended for use during pregnancy. “It is important to emphasise that this is a preventive intervention, not a treatment,” she stated.
Nigeria is one of nine early adopter countries selected by the Global Fund to receive Lenacapavir, following its expression of interest in March 2025. Approximately 52,000 doses have already been delivered to the country, according to Iziaq Salako, Minister of State for Health and Social Welfare.
The move is part of a broader national strategy to end HIV/AIDS as a public health threat by 2030. Despite improvements in access to antiretroviral therapy, prevention gaps remain, particularly among young people and key populations facing stigma, limited awareness, and inconsistent access to services.
Nigeria currently ranks fourth globally in terms of HIV burden, with an estimated 1.9 million people living with the virus, according to NACA.
Officials stressed that Lenacapavir is not a standalone solution. “We must stress that it does not prevent sexually transmitted infections, unwanted pregnancy or other infections like hepatitis,” Ilori cautioned. “People must continue to take comprehensive precautions.”
Adebobola Bashorun, National Coordinator of the National HIV, Viral Hepatitis and STDs Control Programme (NASCP), highlighted that the rollout plan was informed by programme data and stakeholder collaboration. He added that the drug will complement existing prevention options, including oral PrEP and long-acting injectable cabotegravir, expanding choices for those at risk.
The government plans a phased rollout, with ongoing monitoring of safety outcomes before nationwide expansion. Discussions are also underway regarding potential local production of the drug to ensure long-term sustainability and reduce reliance on external donors.
